2014
Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance)
Klepin HD, Pitcher BN, Ballman KV, Kornblith AB, Hurria A, Winer EP, Hudis C, Cohen HJ, Muss HB, Kimmick GG. Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance). JCO Oncology Practice 2014, 10: e285-e292. PMID: 25074878, PMCID: PMC4161730, DOI: 10.1200/jop.2014.001388.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBreast NeoplasmsCapecitabineChemotherapy, AdjuvantComorbidityDeoxycytidineDisease-Free SurvivalFemaleFluorouracilHumansKaplan-Meier EstimateMultivariate AnalysisProportional Hazards ModelsQuality of LifeRegression AnalysisSurveys and QuestionnairesTreatment OutcomeConceptsOverall survivalAdjuvant chemotherapyBurden scoreBreast cancerOlder womenShorter OSClinical trialsEarly-stage breast cancerCox proportional hazards modelStandard adjuvant chemotherapyNumber of comorbiditiesHazard of deathPhysical health subscaleOlder Americans ResourcesProportional hazards modelCALGB 49907Chemotherapy toxicityReceptor statusComorbid conditionsTumor sizeHealth subscaleGrade 3ComorbiditiesCommon conditionHazards model
2013
Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC).
Freedman R, Luis I, Lin N, Lii J, Winer E, Keating N. Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 616-616. DOI: 10.1200/jco.2013.31.15_suppl.616.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancerAdjuvant trastuzumabCardiac eventsOlder womenTrastuzumab completionOlder patientsHospital admissionDays of therapyTaxane-based therapyMultivariable logistic regressionMore comorbiditiesLower oddsHispanic womenMedicare dataTrastuzumabPatientsTherapyLogistic regressionWomenComorbiditiesChemotherapyAdmissionOne-quarterTreatmentDifferences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance).
Polite B, Allred J, Rugo H, Cipriano T, Cirrincione C, Gehlert S, Paskett E, Hudis C, Winer E. Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance). Journal Of Clinical Oncology 2013, 31: 9581-9581. DOI: 10.1200/jco.2013.31.15_suppl.9581.Peer-Reviewed Original ResearchMetastatic breast cancer trialsBreast cancer trialsCancer trialsRace/ethnicitySocial supportBreast cancer patientsLower overall survivalLow social supportAfrican American womenSocio-demographic factorsOverall survivalHispanic patientsCancer patientsHigh comorbiditySelf-identified race/ethnicityPsychosocial factorsSelf-administered surveyPatientsLow levelsMarital statusEthnic differencesSurvivalTrialsComorbiditiesAmerican women
2010
Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians
Mandelblatt JS, Sheppard VB, Hurria A, Kimmick G, Isaacs C, Taylor KL, Kornblith AB, Noone AM, Luta G, Tallarico M, Barry WT, Hunegs L, Zon R, Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H. Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians. Journal Of Clinical Oncology 2010, 28: 3146-3153. PMID: 20516438, PMCID: PMC2903313, DOI: 10.1200/jco.2009.24.3295.Peer-Reviewed Original ResearchConceptsChemotherapy usePatient preferencesChemotherapy decisionsOlder womenCooperative group sitesAdjuvant chemotherapy decisionsNonmetastatic breast cancerHigher patient ratingsTimes higher oddsPatient ageChemotherapy ratesPatient interviewsProvider communicationPatient ratingsBreast cancerPhysician surveyHigher oddsChemotherapyLogistic regressionWomenLimited dataWomen's preferencesImportant correlatesGroupComorbidities